141 related articles for article (PubMed ID: 20981126)
1. Chemotherapy: Lo and behold, a role for lomustine in acute myeloid leukemia?
Appelbaum FR
Nat Rev Clin Oncol; 2010 Nov; 7(11):619-21. PubMed ID: 20981126
[No Abstract] [Full Text] [Related]
2. Adding lomustine to idarubicin and cytarabine for induction chemotherapy in older patients with acute myeloid leukemia: the BGMT 95 trial results.
Pigneux A; Perreau V; Jourdan E; Vey N; Dastugue N; Huguet F; Sotto JJ; Salmi LR; Ifrah N; Reiffers J
Haematologica; 2007 Oct; 92(10):1327-34. PubMed ID: 18024370
[TBL] [Abstract][Full Text] [Related]
3. Is obesity a prognostic factor for acute myeloid leukemia outcome?
Lee HJ; Licht AS; Hyland AJ; Ford LA; Sait SN; Block AW; Barcos M; Baer MR; Wang ES; Wetzler M
Ann Hematol; 2012 Mar; 91(3):359-65. PubMed ID: 21935651
[TBL] [Abstract][Full Text] [Related]
4. Lomustine is beneficial to older AML with ELN2017 adverse risk profile and intermediate karyotype: a FILO study.
Largeaud L; Cornillet-Lefebvre P; Hamel JF; Dumas PY; Prade N; Dufrechou S; Plenecassagnes J; Luquet I; Blanchet O; Banos A; Béné MC; Bernard M; Bertoli S; Bonmati C; Fornecker LM; Guièze R; Haddaoui L; Hunault M; Ianotto JC; Jourdan E; Ojeda M; Peterlin P; Vey N; Zerazhi H; Yosr H; Mineur A; Cahn JY; Ifrah N; Récher C; Pigneux A; Delabesse E;
Leukemia; 2021 May; 35(5):1291-1300. PubMed ID: 32943750
[TBL] [Abstract][Full Text] [Related]
5. Can we improve outcomes in patients with acute myelogenous leukemia? Incorporating HDAC inhibitors into front-line therapy.
Garcia-Manero G
Best Pract Res Clin Haematol; 2012 Dec; 25(4):427-35. PubMed ID: 23200539
[TBL] [Abstract][Full Text] [Related]
6. Acute basophilic leukemia.
Eveillard M; Desjonqueres A
Blood; 2014 May; 123(20):3071. PubMed ID: 24949509
[No Abstract] [Full Text] [Related]
7. [Klinefelter syndrome and acute myeloblastic leukaemia].
Bellaaj H; Sandi HS; Kammoun H; Kallel C; Kassar O; Elloumi M
Presse Med; 2009 Jun; 38(6):1019-22. PubMed ID: 19167185
[No Abstract] [Full Text] [Related]
8. Time from diagnosis to intensive chemotherapy initiation does not adversely impact the outcome of patients with acute myeloid leukemia.
Bertoli S; Bérard E; Huguet F; Huynh A; Tavitian S; Vergez F; Dobbelstein S; Dastugue N; Mansat-De Mas V; Delabesse E; Duchayne E; Demur C; Sarry A; Lauwers-Cances V; Laurent G; Attal M; Récher C
Blood; 2013 Apr; 121(14):2618-26. PubMed ID: 23365464
[TBL] [Abstract][Full Text] [Related]
9. Biphenotypic acute leukemia treated with acute myeloid leukemia regimens: a case series.
Serefhanoglu S; Buyukasik Y; Goker H; Sayinalp N; Ozcebe OI
J Natl Med Assoc; 2009 Mar; 101(3):270-2. PubMed ID: 19331261
[TBL] [Abstract][Full Text] [Related]
10. [Diagnostic image (92). A man with fever during chemotherapy. Invasive pulmonary mycosis].
van Spronsen DJ; Daenen SM; Kluin-Nelemans JC
Ned Tijdschr Geneeskd; 2002 Jun; 146(24):1126. PubMed ID: 12092303
[TBL] [Abstract][Full Text] [Related]
11. Life-threatening conjunctival presentation of myeloid sarcoma.
Alexander C; Lee GA; Whitehead K; Bashford J; Jefferies PD
Clin Exp Ophthalmol; 2008 Nov; 36(8):775-7. PubMed ID: 19128384
[TBL] [Abstract][Full Text] [Related]
12. [Research results and prospects in the field of experimental leukemia chemotherapy].
Kozinets GI; Khomchenovskiĭ EI; Reshchikov VP; Khanykova OK; Egorov LV
Probl Gematol Pereliv Krovi; 1979 Jan; 24(1):3-7. PubMed ID: 368760
[No Abstract] [Full Text] [Related]
13. Idarubicin plus behenoyl cytarabine and 6-thioguanine compares favorably with idarubicin plus cytarabine-based regimen for children with previously untreated acute myeloid leukemia: 10-year retrospective, multicenter study in Korea.
Lee DH; Chung NG; Cho B; Kim HK; Kang HJ; Shin HY; Ahn HS; Yoo KH; Sung KW; Koo HH; Kook H; Hwang TJ; Im HJ; Seo JJ; Park HJ
J Korean Med Sci; 2010 Jan; 25(1):9-15. PubMed ID: 20052341
[TBL] [Abstract][Full Text] [Related]
14. Addition of lomustine to idarubicin and cytarabine improves the outcome of elderly patients with de novo acute myeloid leukemia: a report from the GOELAMS.
Pigneux A; Harousseau JL; Witz F; Sauvezie M; Bene MC; Luquet I; Hunault-Berger M; Recher C; Lioure B; Himberlin C; Escoffre-Barbe M; Berthou C; Lissandre S; Fegueux N; Cahn JY; Jourdan E; Dreyfus F; Reiffers J; Milpied N; Ifrah N
J Clin Oncol; 2010 Jun; 28(18):3028-34. PubMed ID: 20479424
[TBL] [Abstract][Full Text] [Related]
15. Reticulate Hyperpigmentation secondary to 5-fluorouracil and idarubicin.
Jogi R; Garman M; Pielop J; Orengo I; Hsu S
J Drugs Dermatol; 2005; 4(5):652-6. PubMed ID: 16167426
[TBL] [Abstract][Full Text] [Related]
16. Anticancer chemotherapy.
Davey P; Tudhope GR
Br Med J (Clin Res Ed); 1983 Jul; 287(6385):110-3. PubMed ID: 6407699
[No Abstract] [Full Text] [Related]
17. [Foundations of the therapy of inoperable malignomas and hemoblastoses].
Stacher A
Wien Med Wochenschr; 1976 Jan; 126(5):51-4. PubMed ID: 948909
[No Abstract] [Full Text] [Related]
18. 1-(2-Chloroethyl)-cyclohexyl-nitrosourea-induced remission in essential thrombocythemia.
Leoni F; Grossi A; Rossi Ferrini P
Acta Haematol; 1983; 69(3):180-3. PubMed ID: 6404101
[TBL] [Abstract][Full Text] [Related]
19. Lomustine in older patients with acute myeloid leukaemia.
Gourd E
Lancet Oncol; 2018 Nov; 19(11):e584. PubMed ID: 30293791
[No Abstract] [Full Text] [Related]
20. Co-existence of acute myeloid leukemia infiltration and extramedullary hematopoiesis in appendix.
Vasudevan JA; Nair RA; Prem S; Nair CK
Indian J Pathol Microbiol; 2014; 57(4):638-9. PubMed ID: 25308028
[No Abstract] [Full Text] [Related]
[Next] [New Search]
